Submitted by Anonymous (not verified) on 12 July 2024 - 13:40
Opinion/decision on a Paediatric investigation plan (PIP): Kevzara, sarilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0258/2023
Source: